drugset / Trial / NCT00621218

A Study to Determine the Safety and Efficacy of Atralin (Tretinoin 0.05%) Gel for the Treatment of Rosacea

NCT00621218

Phase 2 Completed 36 enrolled Coria Laboratories, Ltd.
RandomizedParallel-groupDouble-blindTreatment

Summary

To compare the efficacy and safety of tretinoin gel 0.05% to its vehicle when dosed once or twice daily in female subjects with rosacea.

Timeline

Start
2008-02
Primary completion
2008-04
Completion
2008-12

Drugs

EvaluationDrugModalityDoseRoute
Comparator Tretinoin Small molecule 0.05 % Topical

Indications